Biotech Values

[DewDiligence]

GILD has some credibility problems in HCV, as you know from following ACHN. Since GS9190 appears to be wanting, to become a serious HCV player GILD will have to either fall back on its three very-early-stage compounds (see first paragraph of #msg-49224935) or build on GS9256 by partnering with a company such as IDIX, VRUS, or INHX.